Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06556368 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Phase 3 study of Wet Age-related Macular Degeneration, sponsored by Kodiak Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 20
- Study locations
NCT06556368: Active Phase 3 study of Wet Age-related Macular Degeneration, sponsored by Kodiak Sciences.
NCT06556368 is a Phase 3 study of Wet Age-related Macular Degeneration that is active but no longer recruiting, run by Kodiak Sciences. The registered enrollment target is 675 participants, above the 340-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06556368, a Phase 3 study of Wet Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Kodiak Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Primary Outcome
Mean change in BCVA from Day 1 to Year 1
Conditions Studied
Interventions
- DRUG Aflibercept
- DRUG Tarcocimab tedromer
- DRUG Tabirafusp tedromer
Study Locations (20)
California
- Retina Consultants of Orange County - Fullerton
- Global Research Management, Inc. - Lugene Eye Institute - Glendale
- Retinal Consultants Medical Group, Inc. - Modesto
- California Eye Specialists Medical Group, Inc. - Pasadena
- California Eye Specialists Medical Group, Inc. - Redlands
- Retinal Consultants Medical Group Inc - Sacramento
Florida
- Blue Ocean Clinical Research - Clearwater
- Retina Group of Florida - Fort Lauderdale
- National Ophthalmic Research Institute - Fort Myers
- Retina Group of Florida - Sarasota
- Center for Retina and Macular Disease - Winter Haven
Arizona
- Associated Retina Consultants - Gilbert
- Associated Retina Consultants - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
- Retina Associates SW - Tucson
Illinois
- Retina Associates, Ltd - Elmhurst
- Illinois Retina Associates - Oak Park
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
Connecticut
- Retina Group of New England, PC - Waterford
Georgia
- Southeast Retina Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What the registry record for NCT06556368 still lists
NCT06556368 is an interventional study that assigns participants to a tested intervention. The registered 675 participants enrollment target is mid-sized for trials with a published cap, above the 340-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (99% higher).
The record links to 1 condition, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Aflibercept is the first listed.
NCT06556368 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06556368 about?
NCT06556368 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK". A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
What is the current status of trial NCT06556368?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2024-08-23. Estimated completion is 2027-08.
What conditions does trial NCT06556368 study?
This clinical trial studies the following conditions: Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT06556368?
The interventions under investigation include: Aflibercept (DRUG), Tarcocimab tedromer (DRUG), Tabirafusp tedromer (DRUG).
Who is sponsoring clinical trial NCT06556368?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06556368 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wet Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06556368's enrollment target sits among peer trials
675 1st of 8 higher than 8 of 8 other Wet Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wet Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
COMPLETED · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
- NCT06357533 · 675 participants · Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI